



**7th Baltic  
Atherosclerosis Congress**  
April 6-7, 2018 Tallinn, Estonia



Dear doctor,

**AstraZeneca** would like to invite you to the Satellite Symposia

**Date & time:** Friday, April 6th 17:50 - 18:35

**Meeting venue:** conference main hall "Grande", Original Sokos Hotel Viru, Viru väljak 4, Tallinn

## **Treat to success or treat to failure. What does real life tell us about Type 2 DM?**



**Assoc. Prof.  
Kristine Ducena**

### **Speakers**



**Assoc. Prof.  
Karlis Trusinskis**

### **Synopsis:**

What would be the best way to manage patient with Type 2 DM and CVD? CVD symptoms in diabetics are more often silent or atypical what makes early diagnose of the disease difficult. Studies highlight opportunities to intervene and stop cardiovascular triad development in early stages of T2DM. A new paradigm of treatment goes beyond glucose control: the optimal management is focusing on control of CV risk factors at the same time avoiding renal complications. Declining eGFR leads to increased CV mortality, these factors are closely linked. The question remains: How to improve outcome for patients with T2D?

Cardiologist Assoc. Prof. Karlis Trusinskis and endocrinologists Assoc. Prof. Kristine Ducena will have a debate on stage based on MI patient story.

**We hope that you find the topics interesting and look forward to meeting you for a good discussion.**

**ENTRANCE ONLY FOR PARTICIPANTS REGISTERED TO 7th BALTIC ATHEROSCLEROSIS CONGRESS.**

AstraZeneca Eesti OÜ, Järvevana tee 9, 11314, Tallinn, Estonia, tel. +372 654 9600, e-mail estonia@astrazeneca.com  
XB-0184-02-18-CV